Connect with us

Business

A Narcan Shot for a Fentanyl Overdose, But Can CBD Reverse Any Fentanyl Damage in Your Body?

Published

on

Can CBD Help reverse the effects on Fentanyl in your body?

The drug naloxone serves as a crucial lifesaving remedy against opiate drug overdoses, including substances like fentanyl. Studies indicate that naloxone has resulted in a 75-100% survival rate among overdose victims who received treatment with it. Marketed as Narcan and included in overdose-prevention kits, this medication has saved tens of thousands of lives.

Presently, scientists are actively investigating the possibility of augmenting naloxone’s efficacy by integrating derivatives of cannabidiol (CBD), a compound present in cannabis. Ongoing research aims to ascertain whether CBD derivatives can amplify the lifesaving abilities of naloxone even further.

What Is Fentanyl?

Fentanyl, a synthetic opioid, possesses a potency that surpasses heroin by up to 50 times and morphine by 100 times. This significantly contributes to fatal and nonfatal overdoses in the United States.

There exist two types of fentanyl: pharmaceutical fentanyl and illegally manufactured fentanyl. Both fall under the category of synthetic opioids. Pharmaceutical fentanyl is legitimately prescribed by medical professionals to manage severe pain, particularly after surgeries or for patients with advanced-stage cancer.

However, most recent fentanyl-related overdose cases are associated with illegally produced fentanyl. Illicitly distributed through illegal drug markets, it is sought after for its heroin-like effects. This dangerous substance is often mixed with other drugs due to its incredible potency, leading to cheaper, more potent, addictive, and ultimately more dangerous combinations.

Fentanyl and Overdose

Fentanyl and other synthetic opioids are responsible for the highest overdose deaths. Even in minute quantities, fentanyl can prove lethal, with over 150 individuals succumbing to synthetic opioid-related overdoses daily.

A dangerous aspect of fentanyl is that drugs may contain deadly levels without visible taste or odor clues. Detecting fentanyl in drugs is exceedingly difficult unless you utilize fentanyl test strips.

These budget-friendly test strips usually yield results within 5 minutes, making them potentially lifesaving. However, caution’s imperative since certain test strips may not identify extremely potent fentanyl-like drugs like carfentanil. Therefore, remaining vigilant is essential, even if the test yields a negative result.

Combining Naloxone and CBD

Naloxone works by competing for opioid receptor sites in the brain with opiates such as heroin and morphine. This mechanism successfully blocks the central nervous system’s depressing effects of opioids, reducing the potential halt of breathing that may happen with an overdose.

However, fentanyl exhibits a high affinity for these receptor sites, sometimes necessitating multiple doses of Narcan (naloxone) to prevent overdoses. According to Dr. Alex Straiker, the other primary investigator of the research and a fellow scientist at Indiana University Bloomington, CDC guidelines indicate that fentanyl overdoses may necessitate more than one Narcan dose. Synthetic opioids, including fentanyl, are responsible for over 80% of opiate overdoses.

In response to this challenge, a higher dose of Narcan was approved to address the increasing number of deaths related to synthetic opioids. This was particularly significant as cities like Dayton reported instances where multiple expended ampoules of naloxone were found alongside bodies.

Previous research indicates that CBD may interfere with opioid binding by altering the shape of receptor sites, potentially enhancing the effectiveness of naloxone treatment. Dr. Straiker emphasizes the importance of exploring alternative approaches since naloxone remains the sole drug to reverse opioid overdoses.

Combating Fentanyl Overdose

Indiana University researchers have uncovered a promising breakthrough in treating drug overdoses, particularly from substances like fentanyl. Their study, featured in the Journal of Medicinal Chemistry on July 12, focuses on a modified form of cannabidiol, a cannabis-derived compound that may reverse overdose effects.

The researchers are optimistic that this discovery could pave the way for a novel approach to countering overdoses, either by developing a new product or by synergizing with naloxone, the widely used antidote for opiate overdoses.

The Canadian government’s data reveals that approximately 20 people die daily from apparent opioid toxicity, with synthetic opioids, notably fentanyl, playing a significant role. While naloxone has been effective against opiate overdoses, it proves less potent when combating synthetic opioids within the fentanyl category.

To reverse the effects of an overdose, the body’s opioid receptors require an alternative binding partner. The researchers found that synthetic opiates, including fentanyl, bind tightly to these receptors, making it challenging for naloxone to compete effectively.

In a fentanyl overdose, naloxone and fentanyl bind to different receptor sites, resulting in no competition. To address this, the researchers explored the potential of a negative allosteric modulator, aiming to reverse the effects of fentanyl and its impact on opioid receptors.

As per the University of Michigan, an allosteric modulator is a molecule that interacts with other molecules to influence their behavior.

To identify a potential solution for countering the effects of fentanyl, researchers evaluated 50 chemical compounds through experimentation. Among these compounds, cannabidiol (CBD) demonstrated the ability to act as a negative allosteric modulator at the binding site. However, initial testing required high concentrations of CBD.

After making modifications to enhance CBD’s effectiveness, researchers successfully reversed the effects of fentanyl in blood or tissue samples.

“We’ve pinpointed essential structural components responsible for the desired antidote effect,” explained Straiker. “Some of these compounds exhibit much greater potency than the lead compound. We’ve collaborated with another laboratory to model the binding site, which could aid in identifying additional promising compounds for further study.”

The next crucial phase, as outlined in the study, involves testing these findings on live subjects to ascertain their ability to reverse respiratory depression, a critical aspect of drug overdoses.

Conclusion

The research conducted by Indiana University on a modified form of cannabidiol (CBD) as a potential antidote for fentanyl overdose holds excellent promise. The study’s findings highlight the potential of CBD as a negative allosteric modulator capable of countering the effects of fentanyl. Further advancements in testing and modifications have shown encouraging results in reversing fentanyl’s impact on blood and tissue samples.

As the research progresses, the next critical step involves testing these promising findings on live subjects to determine whether CBD can effectively reverse respiratory depression during drug overdoses. The potential implications of this breakthrough could pave the way for a novel approach to combating fentanyl-related overdoses and saving lives in the future.

Source: https://cannabis.net/blog/medical/a-narcan-shot-for-a-fentanyl-overdose-but-can-cbd-reverse-any-fentanyl-damage-in-your-body

Business

New Mexico cannabis operator fined, loses license for alleged BioTrack fraud

Published

on

New Mexico regulators fined a cannabis operator nearly $300,000 and revoked its license after the company allegedly created fake reports in the state’s traceability software.

The New Mexico Cannabis Control Division (CCD) accused marijuana manufacturer and retailer Golden Roots of 11 violations, according to Albuquerque Business First.

Golden Roots operates the The Cannabis Revolution Dispensary.

The majority of the violations are related to the Albuquerque company’s improper use of BioTrack, which has been New Mexico’s track-and-trace vendor since 2015.

The CCD alleges Golden Roots reported marijuana production only two months after it had received its vertically integrated license, according to Albuquerque Business First.

Because cannabis takes longer than two months to be cultivated, the CCD was suspicious of the report.

After inspecting the company’s premises, the CCD alleged Golden Roots reported cultivation, transportation and sales in BioTrack but wasn’t able to provide officers who inspected the site evidence that the operator was cultivating cannabis.

In April, the CCD revoked Golden Roots’ license and issued a $10,000 fine, according to the news outlet.

The company requested a hearing, which the regulator scheduled for Sept. 1.

At the hearing, the CCD testified that the company’s dried-cannabis weights in BioTrack were suspicious because they didn’t seem to accurately reflect how much weight marijuana loses as it dries.

Company employees also poorly accounted for why they were making adjustments in the system of up to 24 pounds of cannabis, making comments such as “bad” or “mistake” in the software, Albuquerque Business First reported.

Golden Roots was fined $298,972.05 – the amount regulators allege the company made selling products that weren’t properly accounted for in BioTrack.

The CCD has been cracking down on cannabis operators accused of selling products procured from out-of-state or not grown legally:

Golden Roots was the first alleged rulebreaker in New Mexico to be asked to pay a large fine.

Source: https://mjbizdaily.com/new-mexico-cannabis-operator-fined-loses-license-for-alleged-biotrack-fraud/

Continue Reading

Business

Marijuana companies suing US attorney general in federal prohibition challenge

Published

on

Four marijuana companies, including a multistate operator, have filed a lawsuit against U.S. Attorney General Merrick Garland in which they allege the federal MJ prohibition under the Controlled Substances Act is no longer constitutional.

According to the complaint, filed Thursday in U.S. District Court in Massachusetts, retailer Canna Provisions, Treevit delivery service CEO Gyasi Sellers, cultivator Wiseacre Farm and MSO Verano Holdings Corp. are all harmed by “the federal government’s unconstitutional ban on cultivating, manufacturing, distributing, or possessing intrastate marijuana.”

Verano is headquartered in Chicago but has operations in Massachusetts; the other three operators are based in Massachusetts.

The lawsuit seeks a ruling that the “Controlled Substances Act is unconstitutional as applied to the intrastate cultivation, manufacture, possession, and distribution of marijuana pursuant to state law.”

The companies want the case to go before the U.S. Supreme Court.

They hired prominent law firm Boies Schiller Flexner to represent them.

The New York-based firm’s principal is David Boies, whose former clients include Microsoft, former presidential candidate Al Gore and Elizabeth Holmes’ disgraced startup Theranos.

Similar challenges to the federal Controlled Substances Act (CSA) have failed.

One such challenge led to a landmark Supreme Court decision in 2005.

In Gonzalez vs. Raich, the highest court in the United States ruled in a 6-3 decision that the commerce clause of the U.S. Constitution gave Congress the power to outlaw marijuana federally, even though state laws allow the cultivation and sale of cannabis.

In the 18 years since that ruling, 23 states and the District of Columbia have legalized adult-use marijuana and the federal government has allowed a multibillion-dollar cannabis industry to thrive.

Since both Congress and the U.S. Department of Justice, currently headed by Garland, have declined to intervene in state-licensed marijuana markets, the key facts that led to the Supreme Court’s 2005 ruling “no longer apply,” Boies said in a statement Thursday.

“The Supreme Court has since made clear that the federal government lacks the authority to regulate purely intrastate commerce,” Boies said.

“Moreover, the facts on which those precedents are based are no longer true.”

Verano President Darren Weiss said in a statement the company is “prepared to bring this case all the way to the Supreme Court in order to align federal law with how Congress has acted for years.”

While the Biden administration’s push to reschedule marijuana would help solve marijuana operators’ federal tax woes, neither rescheduling nor modest Congressional reforms such as the SAFER Banking Act “solve the fundamental issue,” Weiss added.

“The application of the CSA to lawful state-run cannabis business is an unconstitutional overreach on state sovereignty that has led to decades of harm, failed businesses, lost jobs, and unsafe working conditions.”

Source: https://mjbizdaily.com/marijuana-companies-suing-us-attorney-general-to-overturn-federal-prohibition/

Continue Reading

Business

Alabama to make another attempt Dec. 1 to award medical cannabis licenses

Published

on

Alabama regulators are targeting Dec. 1 to award the first batch of medical cannabis business licenses after the agency’s first two attempts were scrapped because of scoring errors and litigation.

The first licenses will be awarded to individual cultivators, delivery providers, processors, dispensaries and state testing labs, according to the Alabama Medical Cannabis Commission (AMCC).

Then, on Dec. 12, the AMCC will award licenses for vertically integrated operations, a designation set primarily for multistate operators.

Licenses are expected to be handed out 28 days after they have been awarded, so MMJ production could begin in early January, according to the Alabama Daily News.

That means MMJ products could be available for patients around early March, an AMCC spokesperson told the media outlet.

Regulators initially awarded 21 business licenses in June, only to void them after applicants alleged inconsistencies with how the applications were scored.

Then, in August, the state awarded 24 different licenses – 19 went to June recipients – only to reverse themselves again and scratch those licenses after spurned applicants filed lawsuits.

A state judge dismissed a lawsuit filed by Chicago-based MSO Verano Holdings Corp., but another lawsuit is pending.

Source: https://mjbizdaily.com/alabama-plans-to-award-medical-cannabis-licenses-dec-1/

Continue Reading

Trending

Copyright © 2022 420 Reports Marijuana News & Information Website | Reefer News | Cannabis News